T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	active not recruiting	Phase 1	56	University of WashingtonOTHER	1	Sep 29, 2026	clinicaltrials
NCT05821088	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma	active not recruiting	Phase 2	37	David Bond, MDOTHER	1	Jul 20, 2026